The overarching objective of this study is to close clinical knowledge and performance gaps by providing oncology clinicians with the latest advances and emerging research in the evidence-base and personalized treatment of advanced NSCLC patients. In addition, the research team seeks to meet quality measures relevant to value-based care delivery through IT infrastructure and clinical workflow processes. The research team also hopes to gain insights on clinician practice patterns related to advanced NSCLC, and the correlation between advanced NSCLC patients reported goals of care and advanced NSCLC patients' fit/frailty status and treatment decisions.
Name: Carevive CPS
Description: Data collected on the Carevive CPS will be analyzed in order to correlate the patient biomarker testing results with treatment selections.
Measure: Adherence (by providers) to evidence-based treatment recommendations for patients with advanced NSCLC Time: Year 1Description: An in-person workshop will be held at which clinicians treating patients with NSCLC will gather in discussion regarding what value-based care is and how it affects their patients.
Measure: Components of value-based NSCLC cancer care. Time: Year 1Description: Clinician practice patterns of medical oncologists managing older patients with advanced NSCLC, including sub-analyses of practice patterns for those who are considered "fit", "intermediate fit", and "frail," will occur.
Measure: Clinical practice patterns in medical oncologists managing older patients with advanced NSCLC. Time: Year 1Description: To explore how frequently older adults with lung cancer are hospitalized or visit the ER as a result of their lung cancer.
Measure: ER utilization and hospitalization in elderly patients with lung cancer Time: Year 1Allocation: N/A
Single Group Assignment
There is one SNP
For example, the NCCN notes that there is a significant association between EGFR mutations-especially exon 19 deletion and exon 21 (L858R, L861) and exon 18 (G719X, G719) mutations-and sensitivity to TKIs, and that the exon 20 insertion mutation may predict resistance to clinically achievable levels of TKIs. --- L858R ---